 HL/S and EVLA
(SMD, 0.04; 95% CI, -0.14 to 0.22; I2 ¼ 40.6%; 3
studies50,59,107). Disease-speciﬁc QoL 5 years after treatment was better after HL/S than after UGFS (2.60; 95%
CI, 3.99